Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Vita Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Falk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vita Therapeutics

Vita Therapeutics is a cell engineering company, founded out of Johns Hopkins University in 2019, that seeks to develop life-transformative treatments.  The company utilizes induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.  Further, Vita works towards delivering tissue-specific stem cells that have the capability to continue to replicate and support muscle regeneration.  Vita’s lead therapy, VTA-110, is a potential first-in-class allogenic iPSC-based therapy that has shown the ability to repair and regenerate healthy muscle in preclinical studies and has the potential to benefit patients with LGMD and other muscular dystrophies.

To learn more about Vita Therapeutics, visit http://www.vitatx.com/

Contact:
Douglas Falk, Chief Executive Officer
609-339-5126
https://www.linkedin.com/in/douglas-falk-29653057/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved